Gemfibrozil
Tablet · trading as Lopid
To Be Discontinued
FDA shortage record
- Substance
- Gemfibrozil
- Brand name
- Lopid
- Manufacturer
- Parke-Davis Div of Pfizer Inc
- Dosage form
- Tablet
- Presentation
- Lopid, Tablet, 600 mg (NDC 0071-0737-20)
- Route(s)
- ORAL
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
0071-0737-20- Initially posted
- 02/10/2026
- Discontinued
- 02/10/2026
- Current FDA status
- To Be Discontinued
Reason and context
Discontinuation of the manufacture of the drug.
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-533-4535.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
c48855b7-215e-453b-b3b1-a0f9dee7221f). - FDA UNII identifier:
Q8X02027X3. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.